EP3126527A4 - Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline - Google Patents
Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline Download PDFInfo
- Publication number
- EP3126527A4 EP3126527A4 EP15773661.2A EP15773661A EP3126527A4 EP 3126527 A4 EP3126527 A4 EP 3126527A4 EP 15773661 A EP15773661 A EP 15773661A EP 3126527 A4 EP3126527 A4 EP 3126527A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- rasagiline
- determination
- single nucleotide
- nucleotide polymorphisms
- predict response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 102000054765 polymorphisms of proteins Human genes 0.000 title 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title 1
- 229960000245 rasagiline Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461973603P | 2014-04-01 | 2014-04-01 | |
| PCT/US2015/023618 WO2015153629A1 (fr) | 2014-04-01 | 2015-03-31 | Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3126527A1 EP3126527A1 (fr) | 2017-02-08 |
| EP3126527A4 true EP3126527A4 (fr) | 2017-10-04 |
Family
ID=54189487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP15773661.2A Withdrawn EP3126527A4 (fr) | 2014-04-01 | 2015-03-31 | Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150275302A1 (fr) |
| EP (1) | EP3126527A4 (fr) |
| JP (1) | JP2017517481A (fr) |
| AR (1) | AR099950A1 (fr) |
| CA (1) | CA2943841A1 (fr) |
| IL (1) | IL247824A0 (fr) |
| MX (1) | MX2016012718A (fr) |
| TW (1) | TW201621051A (fr) |
| WO (1) | WO2015153629A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087735A1 (fr) * | 2015-11-18 | 2017-05-26 | Millennium Pharmaceuticals, Inc. | Procédé de traitement de la maladie de crohn |
| CN107941953A (zh) * | 2017-11-30 | 2018-04-20 | 天津生机集团股份有限公司 | 一种兽药中金刚烷胺药物残留的检测方法 |
| CN109825572A (zh) * | 2019-03-13 | 2019-05-31 | 陈向东 | 一种检测与异丙酚的敏感性相关基因多态性的试剂盒及其检测方法 |
| CN118406755B (zh) * | 2024-07-02 | 2024-09-10 | 解码(上海)生物医药科技有限公司 | 一种指导帕金森病用药的基因多态性检测引物组及试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090253585A1 (en) * | 2005-11-30 | 2009-10-08 | Luda Diatchenko | Identification of Genetic Polymorphic Variants Associated With Somatosensory Disorders and Methods of Using the Same |
| US20100075308A1 (en) * | 2006-08-01 | 2010-03-25 | The Ohio State University Research Foundation | Polymorphisms in genes affecting cns disorders and uses thereof |
| BRPI0909894A2 (pt) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
| EP2406396A2 (fr) * | 2009-03-12 | 2012-01-18 | Brainco Biopharma, S.L. | Outil de génotypage pour améliorer le pronostic et la gestion clinique de patients atteints de sclérose en plaques |
-
2015
- 2015-03-31 JP JP2016559825A patent/JP2017517481A/ja active Pending
- 2015-03-31 EP EP15773661.2A patent/EP3126527A4/fr not_active Withdrawn
- 2015-03-31 MX MX2016012718A patent/MX2016012718A/es unknown
- 2015-03-31 CA CA2943841A patent/CA2943841A1/fr not_active Abandoned
- 2015-03-31 US US14/674,606 patent/US20150275302A1/en not_active Abandoned
- 2015-03-31 WO PCT/US2015/023618 patent/WO2015153629A1/fr not_active Ceased
- 2015-04-01 TW TW104110766A patent/TW201621051A/zh unknown
- 2015-04-01 AR ARP150101010A patent/AR099950A1/es unknown
-
2016
- 2016-09-14 IL IL247824A patent/IL247824A0/en unknown
Non-Patent Citations (3)
| Title |
|---|
| JOSÉ A G AGÚNDEZ ET AL: "Anti-Parkinson's disease drugs and pharmacogenetic considerations", EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, vol. 9, no. 7, 9 April 2013 (2013-04-09), GB, pages 859 - 874, XP055399975, ISSN: 1742-5255, DOI: 10.1517/17425255.2013.789018 * |
| OLIVIER RASCOL: "A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecifi ed and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes", 7 April 2011 (2011-04-07), XP055046322, Retrieved from the Internet <URL:http://ac.els-cdn.com/S1474442211700734/1-s2.0-S1474442211700734-main.pdf?_tid=ce3cf428-3d3e-11e2-af06-00000aab0f01&acdnat=1354535253_379ce207ffa1d143f20b3614e9683135> [retrieved on 20121203], DOI: 10.1016/S1474- * |
| See also references of WO2015153629A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016012718A (es) | 2016-12-16 |
| JP2017517481A (ja) | 2017-06-29 |
| US20150275302A1 (en) | 2015-10-01 |
| TW201621051A (zh) | 2016-06-16 |
| AR099950A1 (es) | 2016-08-31 |
| EP3126527A1 (fr) | 2017-02-08 |
| WO2015153629A1 (fr) | 2015-10-08 |
| IL247824A0 (en) | 2016-11-30 |
| CA2943841A1 (fr) | 2015-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3194411A4 (fr) | Analogues nucléotidiques | |
| ZA201701246B (en) | Synthesis of dna | |
| EP3160979A4 (fr) | Procédés de préparation d'analogues nucléotidiques substitués | |
| EP3140427A4 (fr) | Biomarqueurs utilisables pour évaluer la réponse aux inhibiteurs de la pi3k | |
| EP3134550A4 (fr) | Détermination de structure à haut rendement à l'aide de calibres d'acides nucléiques | |
| GB2591198B (en) | Biochemical reaction system | |
| EP3230472A4 (fr) | Méthodes et matériaux permettant de prédire une réaction au niraparib | |
| EP3240910A4 (fr) | Pcr quantitative multiplex | |
| EP3377658A4 (fr) | Réactifs nucléotidiques modifiés | |
| EP3189206A4 (fr) | Adjonction de réactifs à base d'aluminium à des flux d'eau contenant des oxyanions | |
| ZA201608555B (en) | Biomarkers for response to ezh2 inhibitors | |
| EP3176269A4 (fr) | Nouveau biomarqueur permettant de prédire la sensibilité à l'inhibiteur de met et son utilisation | |
| IL247824A0 (en) | Single nucleotide polymorphism characterization for predicting response to rasagiline | |
| EP3204469A4 (fr) | Procédé de purification d'une composition organique | |
| GB201400522D0 (en) | Nucleosome substrate assays | |
| EP3095867A4 (fr) | Acide nucléique inhibant l'expression de bêta2gpi | |
| EP3058107A4 (fr) | Polymorphisme d'un seul nucléotide du complexe majeur d'histocompatibilité | |
| HK1228468A1 (en) | Determination of single nucleotide polymorphisms useful to predict response for rasagiline | |
| GB2594163B (en) | Biochemical reaction system | |
| HK1260665A1 (en) | Methods for predicting response to anti-tnf therapy | |
| HK1230671A1 (en) | Biomarkers for response to ezh2 inhibitors | |
| GB2592541B (en) | Biochemical reaction system | |
| EP3259355A4 (fr) | Procédés associés au séquençage de l'adn | |
| HK1236571A (zh) | 聚合酶 | |
| HK1236571A1 (en) | Polymerases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20161031 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: COLLINSON, MAUREEN, SHANNON Inventor name: TCHELET, AMIR Inventor name: GROSSMAN, IRIS Inventor name: KNIGHT, JOANNE Inventor name: MASELLIS, MARIO Inventor name: OFRA, BARNETT Inventor name: EYAL, ELI Inventor name: LEVY, JOSEPH Inventor name: LANG, ANTHONY, EDWARD Inventor name: KENNEDY, JAMES, LOWERY |
|
| DAV | Request for validation of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20170901 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/4985 20060101ALI20170828BHEP Ipc: A61P 25/16 20060101ALI20170828BHEP Ipc: A61K 31/135 20060101ALI20170828BHEP Ipc: A61K 31/4045 20060101ALI20170828BHEP Ipc: A61K 31/428 20060101ALI20170828BHEP Ipc: A61K 31/381 20060101ALI20170828BHEP Ipc: A61K 31/48 20060101ALI20170828BHEP Ipc: A61K 31/198 20060101ALI20170828BHEP Ipc: A61K 31/439 20060101ALI20170828BHEP Ipc: C12Q 1/68 20060101AFI20170828BHEP Ipc: A61K 45/06 20060101ALI20170828BHEP |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1228468 Country of ref document: HK |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20180330 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1228468 Country of ref document: HK |